Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| APPLIED GENETIC TECHNOLOGIES CORPAGTC · Entity 121949 | Director | April 24, 2017 | April 26, 2017 |
| DYNAVAX TECHNOLOGIES CORPDVAX · Entity 66930 | Director | May 28, 2020 | May 29, 2020 |
| KalVista Pharmaceuticals, Inc.KALV · Entity 39180 | Director | October 01, 2020 | October 02, 2020 |
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | Director · 10% owner | September 25, 2020 | October 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
APPLIED GENETIC TECHNOLOGIES CORP
Report date April 24, 2017 · Filed April 26, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | IndirectBy Partnership | 1,404,515 |
Reported balance
After 2017-04-24 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-04-24 · Other · Acquired 3,559 · Balance 1,404,515 F1: Represents cashless exercise of a warrant by InterWest Partners VIII, LP ("IW8"). 7,917 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 11,476 warrants. F4: Shares are owned by IW8. The General Partner of IW8 is InterWest Management Partners VIII, LLC ("IMP8"). The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| CommonSEC Table I · non-derivative | IndirectBy Partnership | 40,181 |
Reported balance
After 2017-04-24 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-04-24 · Other · Acquired 101 · Balance 40,181 F2: Represents cashless exercise of a warrant by InterWest Investors Q VIII, LP ("IIQ8"). 227 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 328 warrants. F5: Shares are owned by IIQ8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| CommonSEC Table I · non-derivative | IndirectBy Partnership | 11,208 |
Reported balance
After 2017-04-24 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-04-24 · Other · Acquired 28 · Balance 11,208 F3: Represents cashless exercise of a warrant by InterWest Investors VIII, LP ("II8"). 63 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 91 warrants. F6: Shares are owned by II8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Warrant to buy CommonSEC Table II · derivative / convertible security · Conversion / exercise price $4.54 · Expires 2017-05-02 | IndirectBy Partnership | 0 |
Reported balance
After 2017-04-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-04-24 · Other · Disposed 11,476 · Balance 0 F4: Shares are owned by IW8. The General Partner of IW8 is InterWest Management Partners VIII, LLC ("IMP8"). The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Warrant to buy CommonSEC Table II · derivative / convertible security · Conversion / exercise price $4.54 · Expires 2017-05-02 | IndirectBy Partnership | 0 |
Reported balance
After 2017-04-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-04-24 · Other · Disposed 328 · Balance 0 F5: Shares are owned by IIQ8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Warrant to buy CommonSEC Table II · derivative / convertible security · Conversion / exercise price $4.54 · Expires 2017-05-02 | IndirectBy Partnership | 0 |
Reported balance
After 2017-04-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-04-24 · Other · Disposed 91 · Balance 0 F6: Shares are owned by II8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents cashless exercise of a warrant by InterWest Partners VIII, LP ("IW8"). 7,917 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 11,476 warrants.
F2: Represents cashless exercise of a warrant by InterWest Investors Q VIII, LP ("IIQ8"). 227 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 328 warrants.
F3: Represents cashless exercise of a warrant by InterWest Investors VIII, LP ("II8"). 63 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 91 warrants.
F4: Shares are owned by IW8. The General Partner of IW8 is InterWest Management Partners VIII, LLC ("IMP8"). The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F5: Shares are owned by IIQ8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F6: Shares are owned by II8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
DYNAVAX TECHNOLOGIES CORP
Report date May 28, 2020 · Filed May 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.84 · Expires 2027-05-27 | Direct | 25,000 |
Reported balance
After 2020-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-28 · Grant · Acquired 25,000 · Balance 25,000 F2: Not applicable. F1: This option vests fully on May 28, 2021, on the one year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests fully on May 28, 2021, on the one year anniversary of the grant date.
F2: Not applicable.
KalVista Pharmaceuticals, Inc.
Report date October 01, 2020 · Filed October 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.88 · Expires 2030-09-30 | Direct | 7,000 |
Reported balance
After 2020-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-01 · Grant · Acquired 7,000 · Balance 7,000 F1: The option vests over a 12 month period: 1/12th on November 1, 2020, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a 12 month period: 1/12th on November 1, 2020, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.
PMV Pharmaceuticals, Inc.
Report date September 25, 2020 · Filed October 02, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 6,469,911 |
Last balance in matching sequence
After 2020-09-29 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2020-09-25 · Purchase · Acquired 55,555 · Balance 55,555 F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Row 2 · 2020-09-29 · Conversion · Acquired 1,620,101 · Balance 1,675,656 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Row 3 · 2020-09-29 · Conversion · Acquired 3,488,398 · Balance 5,164,054 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Row 4 · 2020-09-29 · Conversion · Acquired 1,040,654 · Balance 6,204,708 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Row 5 · 2020-09-29 · Conversion · Acquired 265,203 · Balance 6,469,911 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
| Series Seed Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-29 transaction · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · 2020-09-29 · Conversion · Disposed 1,620,101 · Balance 0 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-29 transaction · row 7
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 7 · 2020-09-29 · Conversion · Disposed 3,488,398 · Balance 0 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-29 transaction · row 8
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 8 · 2020-09-29 · Conversion · Disposed 1,040,654 · Balance 0 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-29 transaction · row 9
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 9 · 2020-09-29 · Conversion · Disposed 265,203 · Balance 0 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.
Past disclosures · reporting ended (5)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVEDRO INC
Report date November 21, 2019 · Filed November 25, 2019
Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, NASR KHALED, Desai Keval, Kliman Gilbert H
Section 16 reporting ended · disclosed 2019-11-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-11-21 · Other · Disposed 2,742,239 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F2: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2019-11-21 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-11-21 · Other · Disposed 3,005 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F3: The securities are directly held by InterWest Venture Management Company ("IVMC"). Gilbert H. Kliman transferred these shares to IVMC for no consideration pursuant to a contractual agreement between Kliman and IW10. Arnold L. Oronsky and Gilbert H. Kliman are owners, directors and officers of IVMC and as such may be deemed to beneficially own the shares held by IVMC. Each of Arnold L. Oronsky and Gilbert H. Kliman disclaim beneficial ownership of such shares except to the extend of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share.
F2: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F3: The securities are directly held by InterWest Venture Management Company ("IVMC"). Gilbert H. Kliman transferred these shares to IVMC for no consideration pursuant to a contractual agreement between Kliman and IW10. Arnold L. Oronsky and Gilbert H. Kliman are owners, directors and officers of IVMC and as such may be deemed to beneficially own the shares held by IVMC. Each of Arnold L. Oronsky and Gilbert H. Kliman disclaim beneficial ownership of such shares except to the extend of his pecuniary interest therein.
Eiger BioPharmaceuticals, Inc.
Report date October 18, 2018 · Filed October 22, 2018
Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, Kliman Gilbert H, Desai Keval, NASR KHALED
Section 16 reporting ended · disclosed 2018-10-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,362,327 |
Last balance in matching sequence
After 2018-10-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-10-18 · Sale · Disposed 210,800 · Balance 1,388,792 F1: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.30 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Row 2 · 2018-10-18 · Sale · Disposed 26,465 · Balance 1,362,327 F2: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.03 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. |
Filing footnotes · ownership attribution and instrument terms
F1: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.30 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.03 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.
TESARO, Inc.
Report date August 07, 2018 · Filed August 09, 2018
Section 16 reporting ended · disclosed 2018-08-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,479 |
Ending reported balance
After 2018-08-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-08-07 · Exercise / conversion · Acquired 10,000 · Balance 12,479 Row 2 · 2018-08-07 · Sale · Disposed 10,000 · Balance 2,479 |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.36 · Expires 2018-08-08 | Direct | 0 |
Reported balance
After 2018-08-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-07 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: The Reporting Person ceased to be a director of the Issuer on May 10, 2018. As such all previously issued NQ Stock Options (right to buy) expired on 08/08/2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person ceased to be a director of the Issuer on May 10, 2018. As such all previously issued NQ Stock Options (right to buy) expired on 08/08/2018.
Venus Concept Inc.
Report date November 07, 2019 · Filed November 13, 2019
Jointly reported with InterWest Partners IX, LP, InterWest Management Partners IX, LLC, NASR KHALED
Section 16 reporting ended · disclosed 2019-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 658,657 |
Reported balance
After 2019-11-07 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-11-07 · Conversion · Acquired 301,605 · Balance 658,657 F1: Received in connection with the Agreement and Plan of Merger and Reorganization dated March 15, 2019, among the Issuer (formerly known as Restoration Robotics, Inc.), Radiant Merger Sub Ltd, an entity organized under the laws of Israel and Venus Concept Ltd, an entity organized under the laws of Israel (the "Merger"), upon the conversion of the outstanding principal and any accrued and unpaid interest of an 8% Convertible Promissory Notes issued by Venus Concept Inc., dated as of February 28, 2019 in the original principal amount of $2,000,000.00 and accrued interest income of $110,027.40. Share data reported herein reflects the 1-for-15 reverse stock split that occurred after the note conversion on November 7, 2019. F3: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664 prior to the 1-for-15 reverse stock split that occurred on November 7, 2019. F2: The securities are directly held by InterWest Partners IX, LP ("IW9"). InterWest Management Partners IX, LLC ("IMP9") as the general partner of IW9, may be deemed to beneficially own the shares held by IW9. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP9, and Khaled A. Nasr is a Venture Member of IMP9. Gilbert H. Kliman is also a Director of the Issuer, and has filed a separate Form 4 in his own name. Each of the foregoing persons may be deemed to beneficially own the shares held by IW9, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. IW9 ceased to be a 10% owner upon closing of the Merger. |
| Unsecured Subordinated Convertible Promissory NoteSEC Table II · derivative / convertible security · Expires 2020-08-28 | Direct | 0 |
Reported balance
After 2019-11-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-07 · Conversion · Disposed Not disclosed · Balance 0 F3: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664 prior to the 1-for-15 reverse stock split that occurred on November 7, 2019. F4: This Unsecured Subordinated Convertible Promissory Note converted upon the consummation of the Merger, pursuant to its terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in connection with the Agreement and Plan of Merger and Reorganization dated March 15, 2019, among the Issuer (formerly known as Restoration Robotics, Inc.), Radiant Merger Sub Ltd, an entity organized under the laws of Israel and Venus Concept Ltd, an entity organized under the laws of Israel (the "Merger"), upon the conversion of the outstanding principal and any accrued and unpaid interest of an 8% Convertible Promissory Notes issued by Venus Concept Inc., dated as of February 28, 2019 in the original principal amount of $2,000,000.00 and accrued interest income of $110,027.40. Share data reported herein reflects the 1-for-15 reverse stock split that occurred after the note conversion on November 7, 2019.
F2: The securities are directly held by InterWest Partners IX, LP ("IW9"). InterWest Management Partners IX, LLC ("IMP9") as the general partner of IW9, may be deemed to beneficially own the shares held by IW9. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP9, and Khaled A. Nasr is a Venture Member of IMP9. Gilbert H. Kliman is also a Director of the Issuer, and has filed a separate Form 4 in his own name. Each of the foregoing persons may be deemed to beneficially own the shares held by IW9, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. IW9 ceased to be a 10% owner upon closing of the Merger.
F3: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664 prior to the 1-for-15 reverse stock split that occurred on November 7, 2019.
F4: This Unsecured Subordinated Convertible Promissory Note converted upon the consummation of the Merger, pursuant to its terms.
Vyome Holdings, Inc
Report date August 06, 2019 · Filed August 08, 2019
Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, Kliman Gilbert H, Desai Keval, NASR KHALED
Section 16 reporting ended · disclosed 2019-08-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 380,224 |
Reported balance
After 2019-08-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-08-06 · Purchase · Acquired 25,000 · Balance 380,224 F1: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F2: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. |
| Warrants (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2024-08-05 | Direct | 18,750 |
Reported balance
After 2019-08-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-08-06 · Purchase · Acquired 18,750 · Balance 18,750 F1: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F2: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants.
F2: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2020 Filed Oct 2, 2020 20:35 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantDirector Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0001209191-20-053394 · doc4.xml · derivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-09-30 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on November 1, 2020, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries C Preferred Stock · Derivative | 265,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052334 · doc4.xml · derivative · entry 9 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 265,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries B Preferred Stock · Derivative | 1,040,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052334 · doc4.xml · derivative · entry 8 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,040,654 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries A Preferred Stock · Derivative | 3,488,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052334 · doc4.xml · derivative · entry 7 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,488,398 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries Seed Preferred Stock · Derivative | 1,620,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052334 · doc4.xml · derivative · entry 6 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,620,101 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 265,203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052334 · doc4.xml · nonDerivative · entry 5 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,469,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 1,040,654 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052334 · doc4.xml · nonDerivative · entry 4 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,204,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 3,488,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052334 · doc4.xml · nonDerivative · entry 3 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,163,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 1,620,101 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052334 · doc4.xml · nonDerivative · entry 2 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,675,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:42 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries C Preferred Stock · Derivative | 265,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053346 · doc4a.xml · derivative · entry 9 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 265,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:42 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries B Preferred Stock · Derivative | 1,040,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053346 · doc4a.xml · derivative · entry 8 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,040,654 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:42 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries A Preferred Stock · Derivative | 3,488,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053346 · doc4a.xml · derivative · entry 7 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,488,398 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:42 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries Seed Preferred Stock · Derivative | 1,620,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053346 · doc4a.xml · derivative · entry 6 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,620,101 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:42 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 265,203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-053346 · doc4a.xml · nonDerivative · entry 5 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,469,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:42 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 1,040,654 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-053346 · doc4a.xml · nonDerivative · entry 4 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,204,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:42 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 3,488,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-053346 · doc4a.xml · nonDerivative · entry 3 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,164,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:42 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 1,620,101 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-053346 · doc4a.xml · nonDerivative · entry 2 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,675,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 16:33 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | PurchaseCommon Stock | 55,000 | $18.00 | $990,000.00 |
DisclosureSEC source: 0001209191-20-052334 · doc4.xml · nonDerivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 55,000 F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 25, 2020 Filed Oct 2, 2020 18:42 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | PurchaseCommon Stock | 55,555 | $18.00 | $999,990.00 |
DisclosureSEC source: 0001209191-20-053346 · doc4a.xml · nonDerivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 55,555 F1 · ownership.nature: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| May 28, 2020 Filed May 29, 2020 16:37 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001209191-20-032958 · doc4.xml · derivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-27 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 28, 2021, on the one year anniversary of the grant date. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 18:26 UTC | AVEDRO INC AVDR · Entity 153528 | OtherCommon Stock | 3,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-028099 · doc4.xml · nonDerivative · entry 2 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F3 · ownership.nature: The securities are directly held by InterWest Venture Management Company ("IVMC"). Gilbert H. Kliman transferred these shares to IVMC for no consideration pursuant to a contractual agreement between Kliman and IW10. Arnold L. Oronsky and Gilbert H. Kliman are owners, directors and officers of IVMC and as such may be deemed to beneficially own the shares held by IVMC. Each of Arnold L. Oronsky and Gilbert H. Kliman disclaim beneficial ownership of such shares except to the extend of his pecuniary interest therein. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 18:26 UTC | AVEDRO INC AVDR · Entity 153528 | OtherCommon Stock | 2,742,239 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-028099 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F2 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| November 07, 2019 Filed Nov 13, 2019 02:01 UTC | Venus Concept Inc. VERO · Entity 55304 | ConversionUnsecured Subordinated Convertible Promissory Note · Derivative | Not disclosed | $0.00 | $2,000,000.00 |
DisclosureSEC source: 0000899243-19-027153 · doc4.xml · derivative · entry 2 InterWest Partners IX, LP · CIK 0001398928 · 10% owner InterWest Management Partners IX, LLC · CIK 0001398927 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 301,605 shares Expires 2020-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664 prior to the 1-for-15 reverse stock split that occurred on November 7, 2019. F4 · derivative.exercise_date: This Unsecured Subordinated Convertible Promissory Note converted upon the consummation of the Merger, pursuant to its terms. Read SEC document |
| November 07, 2019 Filed Nov 13, 2019 02:01 UTC | Venus Concept Inc. VERO · Entity 55304 | ConversionCommon Stock | 301,605 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-027153 · doc4.xml · nonDerivative · entry 1 InterWest Partners IX, LP · CIK 0001398928 · 10% owner InterWest Management Partners IX, LLC · CIK 0001398927 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Received in connection with the Agreement and Plan of Merger and Reorganization dated March 15, 2019, among the Issuer (formerly known as Restoration Robotics, Inc.), Radiant Merger Sub Ltd, an entity organized under the laws of Israel and Venus Concept Ltd, an entity organized under the laws of Israel (the "Merger"), upon the conversion of the outstanding principal and any accrued and unpaid interest of an 8% Convertible Promissory Notes issued by Venus Concept Inc., dated as of February 28, 2019 in the original principal amount of $2,000,000.00 and accrued interest income of $110,027.40. Share data reported herein reflects the 1-for-15 reverse stock split that occurred after the note conversion on November 7, 2019. F3 · price: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664 prior to the 1-for-15 reverse stock split that occurred on November 7, 2019. F2 · balance_after: The securities are directly held by InterWest Partners IX, LP ("IW9"). InterWest Management Partners IX, LLC ("IMP9") as the general partner of IW9, may be deemed to beneficially own the shares held by IW9. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP9, and Khaled A. Nasr is a Venture Member of IMP9. Gilbert H. Kliman is also a Director of the Issuer, and has filed a separate Form 4 in his own name. Each of the foregoing persons may be deemed to beneficially own the shares held by IW9, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. IW9 ceased to be a 10% owner upon closing of the Merger. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 17:25 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $11.21 | $0.00 |
DisclosureSEC source: 0001567619-19-019234 · doc1.xml · derivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2029-10-01 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on November 2, 2019, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 17:58 UTC | Venus Concept Inc. HAIR · Entity 55304 | PurchaseUnsecured Subordinated Convertible Promissory Note · Derivative | Not disclosed | $2,000,000.00 Strike: $0.47 | $2,000,000.00 |
DisclosureSEC source: 0000899243-19-022280 · doc4.xml · derivative · entry 1 InterWest Partners IX, LP · CIK 0001398928 · 10% owner InterWest Management Partners IX, LLC · CIK 0001398927 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 4,288,164 shares Expires 2020-08-28 F1 · derivative.exercise_date: The Promissory Note will convert upon consummation of the transactions contemplated in that certain Agreement and Plan of Merger and Reorganization dated March 15, 2019, among the Issuer, Radiant Merger Sub Ltd., an entity organized under the laws of Israel and Venus Concept Ltd., an entity organized under the laws of Israel. F2 · valueOwnedAfter: The securities are directly held by InterWest Partners IX, LP ("IW9"). InterWest Management Partners IX, LLC ("IMP9") as the general partner of IW9, may be deemed to beneficially own the shares held by IW9. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP9, and Khaled A. Nasr is a Venture Member of IMP9. Gilbert H. Kliman is also a Director of the Issuer, and has filed a separate Form 4 in his own name. Each of the foregoing persons may be deemed to beneficially own the shares held by IW9, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 11:10 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | PurchaseWarrants (Right to buy) · Derivative | 18,750 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0000899243-19-021334 · doc4.xml · derivative · entry 2 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: COMMON · 18,750 shares Expires 2024-08-05 F1 · shares: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F1 · price: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F2 · balance_after: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 11:10 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | PurchaseCommon Stock | 25,000 | $4.00 | $100,000.00 |
DisclosureSEC source: 0000899243-19-021334 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,224 F1 · shares: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F1 · price: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F2 · balance_after: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Read SEC document |
| May 30, 2019 Filed May 31, 2019 18:30 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $4.97 | Not disclosed |
DisclosureSEC source: 0001209191-19-033727 · doc4.xml · derivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-05-29 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 30, 2020, on the one year anniversary of the grant date. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:10 UTC | AVEDRO INC AVDR · Entity 153528 | ConversionSeries CC Convertible Preferred Stock · Derivative | 171,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011329 · doc4.xml · derivative · entry 6 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 171,318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X") as the general partner of InterWest X may be deemed to beneficially own the shares held by InterWest X. Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP X, and Keval Desai and Khaled A. Nasr are venture members of IMP X. Messrs. Kliman, Oronsky, Desai and Nasr may be deemed to beneficially own the shares held by InterWest X. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:10 UTC | AVEDRO INC AVDR · Entity 153528 | ConversionSeries BB Convertible Preferred Stock · Derivative | 222,119 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011329 · doc4.xml · derivative · entry 5 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 222,119 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X") as the general partner of InterWest X may be deemed to beneficially own the shares held by InterWest X. Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP X, and Keval Desai and Khaled A. Nasr are venture members of IMP X. Messrs. Kliman, Oronsky, Desai and Nasr may be deemed to beneficially own the shares held by InterWest X. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:10 UTC | AVEDRO INC AVDR · Entity 153528 | ConversionSeries AA Convertible Preferred Stock · Derivative | 2,247,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011329 · doc4.xml · derivative · entry 4 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,247,190 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X") as the general partner of InterWest X may be deemed to beneficially own the shares held by InterWest X. Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP X, and Keval Desai and Khaled A. Nasr are venture members of IMP X. Messrs. Kliman, Oronsky, Desai and Nasr may be deemed to beneficially own the shares held by InterWest X. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:10 UTC | AVEDRO INC AVDR · Entity 153528 | ConversionCommon Stock | 171,318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-011329 · doc4.xml · nonDerivative · entry 3 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,742,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X") as the general partner of InterWest X may be deemed to beneficially own the shares held by InterWest X. Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP X, and Keval Desai and Khaled A. Nasr are venture members of IMP X. Messrs. Kliman, Oronsky, Desai and Nasr may be deemed to beneficially own the shares held by InterWest X. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:10 UTC | AVEDRO INC AVDR · Entity 153528 | ConversionCommon Stock | 222,119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-011329 · doc4.xml · nonDerivative · entry 2 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,570,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X") as the general partner of InterWest X may be deemed to beneficially own the shares held by InterWest X. Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP X, and Keval Desai and Khaled A. Nasr are venture members of IMP X. Messrs. Kliman, Oronsky, Desai and Nasr may be deemed to beneficially own the shares held by InterWest X. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:10 UTC | AVEDRO INC AVDR · Entity 153528 | ConversionCommon Stock | 2,247,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-011329 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,348,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X") as the general partner of InterWest X may be deemed to beneficially own the shares held by InterWest X. Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP X, and Keval Desai and Khaled A. Nasr are venture members of IMP X. Messrs. Kliman, Oronsky, Desai and Nasr may be deemed to beneficially own the shares held by InterWest X. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 16:33 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 26,465 | $12.00 | $317,606.47 |
DisclosureSEC source: 0000899243-18-027169 · doc4.xml · nonDerivative · entry 2 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,327 F2 · price: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.03 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 16:33 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 210,800 | $12.07 | $2,544,714.36 |
DisclosureSEC source: 0000899243-18-027169 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388,792 F1 · price: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.30 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 18:07 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $22.65 | $0.00 |
DisclosureSEC source: 0001567619-18-003783 · doc1.xml · derivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2028-10-02 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on November 3, 2018, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 19:16 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | PurchaseCommon Stock | 58,824 | $17.00 | $1,000,008.00 |
DisclosureSEC source: 0001567619-18-002466 · doc1.xml · nonDerivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · InterWest Partners IX, L.P. Disclosed balance after: 388,766 F1 · ownership.nature: Shares held by InterWest Partners IX, L.P. is a California limited partnership ("InterWest"), whose general partner is InterWest Management Partners IX, LLC, a California limited liability company. Dr. Oronsky, one of the Company's directors, currently serves as a Managing Director of InterWest. Each managing director and venture member of InterWest Management Partners IX, LLC shares voting and investment power with respect to the securities held by InterWest and disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 16:24 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | PurchaseCommon Stock | 1,098,901 | $1.82 | $1,999,999.82 |
DisclosureSEC source: 0000899243-18-023312 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,552,239 F1 · shares: The reporting person purchased these shares directly from the issuer in a private placement. F2 · balance_after: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:20 UTC | Venus Concept Inc. HAIR · Entity 55304 | PurchaseCommon Stock | 2,000,000 | $1.50 | $3,000,000.00 |
DisclosureSEC source: 0001567619-18-000665 · doc1.xml · nonDerivative · entry 1 InterWest Partners IX, LP · CIK 0001398928 · 10% owner InterWest Management Partners IX, LLC · CIK 0001398927 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,355,786 F1 · kind: The shares were acquired in connection with an underwritten public offering of common stock which is scheduled to close on August 14, 2018. F2 · balance_after: The shares are directly held by InterWest Partners IX, LP ("IW9"). InterWest Management Partners IX, LLC ("IMP9") as the general partner of IW9, may be deemed to beneficially own the shares held by IW9. Arnold L. Oronsky and Gilbert H. Kliman are managing director of IMP9, and Khaled A. Nasr is a Venture Member of IMP9. Each of the foregoing persons may be deemed to beneficially own the shares held by IW9 and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 14:00 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionDirector Nonqualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.36 | $0.00 |
DisclosureSEC source: 0000899243-18-021817 · doc4.xml · derivative · entry 3 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 10,000 shares Expires 2018-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: The Reporting Person ceased to be a director of the Issuer on May 10, 2018. As such all previously issued NQ Stock Options (right to buy) expired on 08/08/2018. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 14:00 UTC | TESARO, Inc. TSRO · Entity 160894 | SaleCommon Stock | 10,000 | $26.77 | $267,721.00 |
DisclosureSEC source: 0000899243-18-021817 · doc4.xml · nonDerivative · entry 2 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,479 Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 14:00 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-021817 · doc4.xml · nonDerivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 17:10 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantOption (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $15.80 | Not disclosed |
DisclosureSEC source: 0001209191-18-034770 · doc4.xml · derivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-05-30 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 31, 2019, on the one year anniversary of the grant date. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 22:44 UTC | Venus Concept Inc. HAIR · Entity 55304 | ConversionConvertible Promissory Note · Derivative | Not disclosed | Not disclosed Strike: $7.00 | $1,183,713.69 |
DisclosureSEC source: 0001140361-17-038922 · doc1.xml · derivative · entry 6 InterWest Partners IX, LP · CIK 0001398928 · 10% owner InterWest Management Partners IX, LLC · CIK 0001398927 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170,028 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · reported_value: The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the "Note"). The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO. F4 · price: The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the "Note"). The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO. F4 · derivative.exercise_date: The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the "Note"). The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO. F4 · derivative.expiration_date: The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the "Note"). The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO. F2 · ownership.direct: The shares are directly held by InterWest Partners IX, LP ("InterWest IX"). InterWest Management Partners IX, LLC ("IMP IX"), as the general partner of InterWest IX, may be deemed to beneficially own the shares held by InterWest IX. Philip Gianos, Arnold Oronsky, Gilbert Kliman, W. Stephen Holmes and Khaled Nasr are managing directors of IMP IX, and as such may be deemed to beneficially own the shares held by InterWest IX. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 22:44 UTC | Venus Concept Inc. HAIR · Entity 55304 | ConversionSeries C Preferred Stock · Derivative | 1,647,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-038922 · doc1.xml · derivative · entry 5 InterWest Partners IX, LP · CIK 0001398928 · 10% owner InterWest Management Partners IX, LLC · CIK 0001398927 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,647,297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F3 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.direct: The shares are directly held by InterWest Partners IX, LP ("InterWest IX"). InterWest Management Partners IX, LLC ("IMP IX"), as the general partner of InterWest IX, may be deemed to beneficially own the shares held by InterWest IX. Philip Gianos, Arnold Oronsky, Gilbert Kliman, W. Stephen Holmes and Khaled Nasr are managing directors of IMP IX, and as such may be deemed to beneficially own the shares held by InterWest IX. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 22:44 UTC | Venus Concept Inc. HAIR · Entity 55304 | ConversionSeries B Preferred Stock · Derivative | 1,538,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-038922 · doc1.xml · derivative · entry 4 InterWest Partners IX, LP · CIK 0001398928 · 10% owner InterWest Management Partners IX, LLC · CIK 0001398927 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,538,461 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F3 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.direct: The shares are directly held by InterWest Partners IX, LP ("InterWest IX"). InterWest Management Partners IX, LLC ("IMP IX"), as the general partner of InterWest IX, may be deemed to beneficially own the shares held by InterWest IX. Philip Gianos, Arnold Oronsky, Gilbert Kliman, W. Stephen Holmes and Khaled Nasr are managing directors of IMP IX, and as such may be deemed to beneficially own the shares held by InterWest IX. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 22:44 UTC | Venus Concept Inc. HAIR · Entity 55304 | ConversionCommon Stock | 170,028 | $7.00 | $1,190,196.00 |
DisclosureSEC source: 0001140361-17-038922 · doc1.xml · nonDerivative · entry 3 InterWest Partners IX, LP · CIK 0001398928 · 10% owner InterWest Management Partners IX, LLC · CIK 0001398927 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,355,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.direct: The shares are directly held by InterWest Partners IX, LP ("InterWest IX"). InterWest Management Partners IX, LLC ("IMP IX"), as the general partner of InterWest IX, may be deemed to beneficially own the shares held by InterWest IX. Philip Gianos, Arnold Oronsky, Gilbert Kliman, W. Stephen Holmes and Khaled Nasr are managing directors of IMP IX, and as such may be deemed to beneficially own the shares held by InterWest IX. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 22:44 UTC | Venus Concept Inc. HAIR · Entity 55304 | ConversionCommon Stock | 1,647,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-038922 · doc1.xml · nonDerivative · entry 2 InterWest Partners IX, LP · CIK 0001398928 · 10% owner InterWest Management Partners IX, LLC · CIK 0001398927 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,185,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F2 · ownership.direct: The shares are directly held by InterWest Partners IX, LP ("InterWest IX"). InterWest Management Partners IX, LLC ("IMP IX"), as the general partner of InterWest IX, may be deemed to beneficially own the shares held by InterWest IX. Philip Gianos, Arnold Oronsky, Gilbert Kliman, W. Stephen Holmes and Khaled Nasr are managing directors of IMP IX, and as such may be deemed to beneficially own the shares held by InterWest IX. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.